MBX Biosciences (MBX) Cash & Equivalents (2023 - 2026)

MBX Biosciences has reported Cash & Equivalents for 4 years, with the latest figure at $45.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 51.2% year-over-year to $45.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.2 million (up 51.2% YoY) and the FY2025 annual result came in at $75.3 million, up 52.56% from the prior year.
• Cash & Equivalents fell to $45.2 million in Q1 2026 per MBX's latest filing, from $75.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $223.1 million in Q3 2025 and troughed at $29.9 million in Q1 2025.
• A 4-year average of $78.3 million and a median of $47.3 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents surged 67.93% in 2025, then surged 51.2% in 2026.
• Over 4 years, Cash & Equivalents stood at $30.5 million in 2023, then surged by 61.68% to $49.4 million in 2024, then surged by 52.56% to $75.3 million in 2025, then sank by 39.95% to $45.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $45.2 million, $75.3 million, and $223.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.